Program
Rifampin
Also written as “Rifampicin”, “rifampicin” and “RSS0343 Tablet; Rifampicin Capsules”.
Its studies are mostly in Neoplasms · Tuberculosis, Pulmonary · Hematologic Neoplasms · Melanoma · Bronchiectasis, led by 28 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 40 open or running | phase 1since Sep 25, 2007 | Sep 25, 2007 | none ahead |
| AstraZeneca | 30 open or running | phase 1since Aug 23, 2013 | Aug 23, 2013 | none ahead |
| HUTCHMED | 30 open or running | phase 1since Aug 10, 2020 | Aug 10, 2020 | none ahead |
| Jiangsu HengRui Medicine | 32 open or running | phase 1since Jul 28, 2020 | Jul 28, 2020 | none ahead |
| Takeda | 30 open or running | phase 1since Jan 23, 2008 | Jan 23, 2008 | none ahead |
| Boehringer Ingelheim | 20 open or running | phase 1since Jun 20, 2014 | Jun 20, 2014 | none ahead |
| GlaxoSmithKline | 20 open or running | phase 2since May 16, 2022 | Sep 26, 2013 | none ahead |
| Hoffmann-La Roche | 20 open or running | phase 1since Jan 9, 2013 | Jan 9, 2013 | none ahead |
| Johnson & Johnson | 20 open or running | phase 1since Jan 23, 2012 | Jan 23, 2012 | none ahead |
| Pfizer | 20 open or running | phase 1since Oct 3, 2006 | Oct 3, 2006 | none ahead |
| PTC Therapeutics | 20 open or running | phase 1since Nov 4, 2014 | Nov 4, 2014 | none ahead |
| Bayer | 10 open or running | phase 1since Nov 4, 2016 | Nov 4, 2016 | none ahead |
| Beijing Aosaikang Pharmaceutical | 10 open or running | phase 1since Nov 11, 2022 | Nov 11, 2022 | none ahead |
| Betta Pharmaceuticals | 11 open or running | phase 1since Jul 1, 2024 | Jul 1, 2024 | none ahead |
| Eisai | 10 open or running | phase 1since Jan 23, 2014 | Jan 23, 2014 | none ahead |
| emalex-biosciences-inc | 10 open or running | phase 1since Dec 22, 2023 | Dec 22, 2023 | none ahead |
| f2g-biotech-gmbh | 10 open or running | phase 1since Nov 19, 2019 | Nov 19, 2019 | none ahead |
| Guangdong Zhongsheng Pharmaceutical | 10 open or running | phase 1since Sep 4, 2023 | Sep 4, 2023 | none ahead |
| Idorsia Pharmaceuticals | 10 open or running | phase 1since Jul 5, 2018 | Jul 5, 2018 | none ahead |
| Ipsen | 10 open or running | phase 1since Jul 29, 2020 | Jul 29, 2020 | none ahead |
| LG Chem | 10 open or running | phase 1since Aug 31, 2011 | Aug 31, 2011 | none ahead |
| phathom-pharmaceuticals-inc | 10 open or running | phase 1since Sep 15, 2020 | Sep 15, 2020 | none ahead |
| SecuraBio | 10 open or running | phase 1since Sep 18, 2013 | Sep 18, 2013 | none ahead |
| Sunshine Lake Pharma | 10 open or running | phase 1since Aug 31, 2021 | Aug 31, 2021 | none ahead |
| thirty-respiratory-limited | 10 open or running | phase 2since Aug 21, 2023 | Aug 21, 2023 | none ahead |
| tyk-medicines-inc | 10 open or running | phase 1since Jan 17, 2024 | Jan 17, 2024 | none ahead |
| vantia-ltd | 10 open or running | phase 1since May 7, 2015 | May 7, 2015 | none ahead |
| Vertex Pharmaceuticals | 10 open or running | phase 1since Nov 19, 2009 | Nov 19, 2009 | none ahead |
Also a collaborator on its studies: cambridge-cognition-ltd, parexel, covance and pra-health-sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 31 studies since Oct 3, 2006.
- Sep 15, 2020Phase 1 study in Drug Drug InteractionHUTCHMED · NCT04557397 · 28 enrolled · United States
- Jun 8, 2021Phase 1 study in Advanced Solid TumoursAstraZeneca · NCT04959266 · 5 enrolled · United States, Spain
- Aug 31, 2021Sunshine Lake Pharma's first study: phase 1 study in Healthy VolunteersNew to Sunshine Lake PharmaSunshine Lake Pharma · NCT05057949 · 32 enrolled · China
- Feb 10, 2022Phase 1 study in Healthy AdultsBristol-Myers Squibb · NCT05255276 · 36 enrolled · United States
- May 16, 2022Phase 2 study in TuberculosisGlaxoSmithKline · NCT05382312 · 127 enrolled · South Africa
- Oct 27, 2022Phase 1 study in RecurrenceHUTCHMED · NCT05602597 · 59 enrolled · United States
- Nov 11, 2022Beijing Aosaikang Pharmaceutical's first study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to Beijing Aosaikang PharmaceuticalBeijing Aosaikang Pharmaceutical · NCT05631678 · 48 enrolled · China
- Aug 21, 2023thirty-respiratory-limited's first study: phase 2 study in Rifampicin Susceptible Pulmonary TuberculosisNew to thirty-respiratory-limitedthirty-respiratory-limited · NCT06041919 · 20 enrolled · South Africa
- Sep 4, 2023Guangdong Zhongsheng Pharmaceutical's first study: phase 1 study in Drug Drug InteractionNew to Guangdong Zhongsheng PharmaceuticalGuangdong Zhongsheng Pharmaceutical · NCT06031454 · 56 enrolled · China
- Dec 22, 2023emalex-biosciences-inc's first study: phase 1 study in Drug InteractionNew to emalex-biosciences-incemalex-biosciences-inc · NCT06194864 · 45 enrolled · Canada
- Jan 17, 2024tyk-medicines-inc's first study: phase 1 study in NSCLCNew to tyk-medicines-inctyk-medicines-inc · NCT06255951 · 48 enrolled · China
- Mar 22, 2024Phase 1 study in Renal Insufficiency, ChronicJiangsu HengRui Medicine · NCT06344936 · 28 planned · China
- Jul 1, 2024Betta Pharmaceuticals's first study: phase 1 study in HealthyNew to Betta PharmaceuticalsBetta Pharmaceuticals · NCT06492525 · 36 planned · China
- Jul 6, 2026Phase 1 study in Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary DiseaseJiangsu HengRui Medicine · NCT07696091 · 40 planned · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Bacterial DNA-directed RNA polymerase inhibitor”ChEMBL 37, by rule
Studies
All 45 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07696091Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary Disease · China | 1 | Not yet recruiting | Jiangsu HengRui Medicine | Sep 2026 | 40 |
| NCT06492525Healthy · China | 1 | Not yet recruiting | Betta Pharmaceuticals | Oct 2024 | 36 |
| NCT06344936Renal Insufficiency, Chronic · China | 1 | Not yet recruiting | Jiangsu HengRui Medicine | Jul 2024 | 28 |
| NCT06255951NSCLC · China | 1 | Completed | tyk-medicines-inc | May 23, 2024 | 48 |
| NCT06194864Drug Interaction · Canada | 1 | Completed | emalex-biosciences-inc | May 14, 2024 | 45 |
| NCT06031454Drug Drug Interaction · China | 1 | Completed | Guangdong Zhongsheng Pharmaceutical | Nov 1, 2023 | 56 |
| NCT06041919Rifampicin Susceptible Pulmonary Tuberculosis · South Africa | 2 | Terminated | thirty-respiratory-limited | Jul 24, 2024 | 20 |
| NCT05631678Carcinoma, Non-Small-Cell Lung · China | 1 | Completed | Beijing Aosaikang Pharmaceutical | Aug 3, 2022 | 48 |
| NCT05602597Recurrence · United States | 1 | Completed | HUTCHMED | Aug 6, 2022 | 59 |
| NCT05382312Tuberculosis · South Africa | 2 | Completed | GlaxoSmithKline | May 27, 2025 | 127 |
| NCT05255276Healthy Adults · United States | 1 | Completed | Bristol-Myers Squibb | May 12, 2022 | 36 |
| NCT05057949Healthy Volunteers · China | 1 | Completed | Sunshine Lake Pharma | Feb 17, 2022 | 32 |
| NCT04959266Advanced Solid Tumours · United States, Spain | 1 | Terminated | AstraZeneca | Jun 1, 2022 | 5 |
| NCT04558216Healthy Participants · United States | 1 | Withdrawn | phathom-pharmaceuticals-inc | Feb 7, 2021 | 0 |
| NCT04557397Drug Drug Interaction · United States | 1 | Completed | HUTCHMED | Oct 18, 2020 | 28 |
| NCT04510649Healthy · United States | 1 | Completed | HUTCHMED | Sep 11, 2020 | 28 |
| NCT04537715Hematologic Neoplasms · United States, Spain | 1 | Completed | Ipsen | Apr 3, 2023 | 42 |
| NCT04494659Healthy Adult Subjects · China | 1 | Completed | Jiangsu HengRui Medicine | Aug 13, 2020 | 21 |
| NCT04171739Healthy · United Kingdom | 1 | Completed | f2g-biotech-gmbh | Feb 11, 2020 | 24 |
| NCT03596294Healthy Subjects · Netherlands | 1 | Completed | Idorsia Pharmaceuticals | Aug 3, 2018 | 14 |
| NCT03486314Advanced Solid Neoplasm · United States | 1 | Completed | Takeda | May 10, 2019 | 20 |
| NCT03307252Healthy · Germany | 1 | Completed | Boehringer Ingelheim | May 2, 2018 | 45 |
| NCT02975440Endometriosis · Germany | 1 | Completed | Bayer | Jan 27, 2017 | 12 |
| NCT02770222Healthy Subjects | 1 | Completed | Johnson & Johnson | Jul 2016 | 40 |
| NCT02608034Melanoma · United States, Israel, Korea, Republic of and more | 1 | Completed | Hoffmann-La Roche | Sep 10, 2018 | 32 |
| NCT02440841Nocturia · Germany | 1 | Completed | vantia-ltd | Jul 2015 | 29 |
| NCT02409004Healthy · Canada | 1 | Completed | PTC Therapeutics | Mar 2015 | 15 |
| NCT02286635Healthy Volunteers · United States | 1 | Completed | PTC Therapeutics | Dec 2014 | 58 |
| NCT02173717Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2009 | 24 |
| NCT02046850Solid Tumours · United States | 1 | Completed | AstraZeneca | Apr 2014 | 24 |
| NCT02055703Healthy Subjects · United States | 1 | Completed | Eisai | Apr 2014 | 195 |
| NCT01954043Neoplasms · United States, Australia, United Kingdom | 1 | Completed | GlaxoSmithKline | Feb 29, 2016 | 23 |
| NCT01950364Hodgkin Disease · Belgium, Lithuania, Spain | 1 | Completed | Takeda | Oct 2014 | 20 |
| NCT01947777Healthy · United States | 1 | Completed | SecuraBio | Nov 2013 | 14 |
| NCT01929603Neoplasms · Belgium, Netherlands | 1 | Completed | AstraZeneca | May 2014 | 32 |
| NCT01765543Melanoma · United States, Brazil, Croatia and more | 1 | Completed | Hoffmann-La Roche | Nov 2015 | 27 |
| NCT01655147Healthy · Belgium | 1 | Completed | Johnson & Johnson | Mar 2012 | 19 |
| NCT01426906Healthy Male Volunteers · Korea, Republic of | 1 | Completed | LG Chem | Mar 2011 | 24 |
| NCT01324323Hematologic Neoplasms · United States, United Kingdom | 1 | Completed | Bristol-Myers Squibb | Feb 1, 2012 | 14 |
| NCT01311505Tuberculosis · Philippines | 1 | Completed | Pfizer | May 2011 | 21 |
| NCT01018368Cystic Fibrosis · United States | 1 | Completed | Vertex Pharmaceuticals | Mar 2010 | 24 |
| NCT01002079Alzheimer Disease · India | 1 | Completed | Bristol-Myers Squibb | Oct 2010 | 20 |
| NCT00608907Multiple Myeloma · Israel, Italy, Poland and more | 1 | Completed | Takeda | Mar 2010 | 61 |
| NCT00534807Neoplasms · United States | 1 | Withdrawn | Bristol-Myers Squibb | Nov 2008 | 0 |
| NCT00384280Healthy | 1 | Completed | Pfizer | Nov 2006 | 24 |
How it is read
Names in the registry
- “Rifampin”, 18 entries
- “Rifampicin”, 9 entries
- “rifampicin”, 5 entries
- “RSS0343 Tablet; Rifampicin Capsules”, 1 entry
- “RIFAFOUR e-275”, 1 entry
Conditions, from the studies’ own filings
- Neoplasms, 3 studies
- Tuberculosis, Pulmonary, 2 studies
- Hematologic Neoplasms, 2 studies
- Melanoma, 2 studies
- Bronchiectasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.